Research News
Nominations Open for Rosalind Franklin Prize for Excellence in Ovarian Cancer Research
OCRA is now accepting nominations for the Rosalind Franklin Prize for Excellence in Ovarian Cancer Research. The deadline to submit a nomination is 5:00pm ET on October 31, 2022…
Study Finds Frequent Aspirin Use is Associated with Reduction in Ovarian Cancer Risk
A recent study partly funded by OCRA, and published in the Journal of Clinical Oncology, has shown that frequent aspirin use (defined as more than six times per week for more than six months) is associated with a reduction in ovarian cancer risk…
Multimodal Study Uses Machine Learning to Improve Risk-Stratification of HGSOC
A recent study published in Nature Cancer talks about harnessing the power of machine learning to help predict prognosis and response to treatment for those with high-grade serous ovarian cancer (HGSOC)…
OCRA-Funded Study Reveals Promising Therapeutic Option for Boosting Ovarian Cancer Immune Response
Targeting a specific oncogene associated with the most common type of ovarian cancer may help increase a patient’s immune response to tumors, according to recent findings from researchers at The Wistar Institute and their colleagues at University…
New Bioinformatics Tool Shows Promise for Matching Cancer Patients with Optimal Treatment Combinations
Recent OCRA-funded research has resulted in the creation of a new bioinformatics tool that holds potential for predicting the best treatment combinations for cancer patients…
Sandra Cascio, PhD | Meet a Scientist
Dr. Sandra Cascio of Magee-Womens Research Institute is a 2021 recipient of OCRA’s Early Career Investigative Grant. With her project, “EGFL6 as a New Regulator of Myeloid Cell Expansion and Function in HGSOC,” Dr…
Martin Cannon, PhD | Meet a Scientist
Dr. Martin Cannon, of University of Arkansas for Medical Sciences (UAMS), is a 2021 recipient of OCRA’s Collaborative Research Development Grant…
Watch Now: What’s New in Ovarian Cancer Research and Treatment
Many exciting updates about progress against ovarian cancer were presented at this year’s Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer — the largest meeting of gynecologic cancer experts in the world…
First Patients Dosed in Phase 2 Platform Clinical Trial Testing Novel Immunotherapy Combinations in Highly Malignant Ovarian Cancer
The following is a press release from Ovarian Cancer Research Alliance and Cancer Research Institute: Patients with ovarian cancer of the high-grade serous carcinoma subtype and that no longer respond to treatment with platinum-based therapy will…
OCRA-Funded Study Pinpoints Partner Proteins That May Contribute to Ovarian Cancer Tumor Growth
The interaction between two partner proteins may promote the growth of the most common ovarian cancer subtype, according to recent findings from OCRA-funded researchers at University of Pennsylvania and Cedars-Sinai Medical Center and their…
New Immunotherapy Combination May Help Combat Ovarian Cancer Tumors
A therapeutic strategy that targets key tumor proteins shows promise for treating the most common subtype of ovarian cancer, according to a recent study led by OCRA grantee Duygu Ozmadenci, PhD, of the University of California, San…
Benoît Bragantini, PhD | Meet a Scientist
Dr. Benoît Brangantini, of Mayo Clinic, is a 2021 recipient of OCRA’s Mentored Investigator Grant. With his project, “Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM,” Dr…